Denali therapeutics announces publication in science translational medicine demonstrating the potential of the oligonucleotide transport vehicle platform to achieve broad biodistribution of antisense oligonucleotides in the cns and muscle following intravenous administration

South san francisco, calif., aug. 14, 2024 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for the treatment of neurodegenerative and lysosomal storage diseases, today announced publication of nonclinical data in the august 14, 2024 issue of science translational medicine (link) demonstrating the ability of the oligonucleotide transport vehicle (otv) platform to achieve broad biodistribution of antisense oligonucleotides (asos) in the central nervous system (cns) and skeletal and cardiac muscle following intravenous (iv) administration.
DNLI Ratings Summary
DNLI Quant Ranking